Skip to main content

Table 3 Drug resistance mutations emerging after incarceration in the ALIVE cohort

From: Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq

Drug class

Mutation

Sample #(s) (% frequency)

Protease inhibitors

L10IFVC

19 (7.9%)

 

V11I

25 (6.0%)

 

G16E

25 (3.2%)

 

K20RMITV

24 (7.0%)

 

M36LIV

24 (5.5%)

 

M46IL

27 (7.3%)

 

F53LY

16 (5.1%)

 

I62V

4 (15.3%)

 

I64LMV

4 (13.7%)

 

G73CSTA

6 (8.1%)

 

V77I

13 (4.6%)

 

L89VIM

22 (3.6%)

 

L90M

6 (16.2%)

NRTI inhibitors

M41L

2 (13.3%)

 

A62V

2 (3.1%)

 

M184V

2 (99.9%), 5 (82.8%), 9 (99.8%), 10 (100%), 16 (56.6%), 23 (68.5%)

NNRTI inhibitors

K103N

5 (100%), 10 (100%), 23 (99.8%)

 

V108I

23 (59.8%)

 

E138KAGQR

16 (7.6%)

 

P225H

23 (55.3%), 10 (99.9%)

Integrase inhibitors

S147G

16 (7.6%)

  1. Boldface font = major mutation. Regular font = accessory mutation.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us